WA40404: A phase IIIb Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis

April 07, 2021
https://clinicaltrials.gov/ct2/show/NCT04035005
Multiple Sclerosis
Principal Investigator: Helena Bulka, DO
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Chronic Progressive
Sclerosis
Accepting Participants
313-916-1482